TapewireFind a company

person · Reporting owner

GOLDFISCHER CARL

Disclosed activity across 5 companies

Tapewire entity
78297
SEC CIK
0001110780

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CymaBay Therapeutics, Inc.CBAY · Entity 92768DirectorFebruary 07, 2019February 08, 2019
Damora Therapeutics, Inc.GLTO · Entity 4602DirectorJune 18, 2025June 20, 2025
Enliven Therapeutics, Inc.IMRA · Entity 4024DirectorJune 02, 2022June 03, 2022
ReShape Weightloss Inc.ETRM · Entity 137993DirectorMay 25, 2017May 31, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CymaBay Therapeutics, Inc.

Report date February 07, 2019 · Filed February 08, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Ending reported balance After 2019-02-07 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2019-02-07 · Exercise / conversion · Acquired 2,335 · Balance 2,335

Row 2 · 2019-02-07 · Exercise / conversion · Acquired 9,340 · Balance 11,675

Row 3 · 2019-02-07 · Sale · Disposed 11,675 · Balance 0

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2023-12-22Direct0 Reported balance After 2019-02-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2019-02-07 · Exercise / conversion · Disposed 2,335 · Balance 0

F2: Fully vested.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2027-06-27Direct0 Reported balance After 2019-02-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2019-02-07 · Exercise / conversion · Disposed 9,340 · Balance 0

F2: Fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: Fully vested.

Damora Therapeutics, Inc.

Report date June 18, 2025 · Filed June 20, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2035-06-18Direct1,440 Reported balance After 2025-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2025-06-18 · Grant · Acquired 1,440 · Balance 1,440

F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

Enliven Therapeutics, Inc.

Report date June 02, 2022 · Filed June 03, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2032-06-01Direct8,500 Reported balance After 2022-06-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2022-06-02 · Grant · Acquired 8,500 · Balance 8,500

F2: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant.

Common StockSEC Table I · non-derivativeIndirectBy entities affiliated with Bay City Capital LLC703,380 Reported balance Holding disclosure · report date 2022-06-02 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 703,380

F1: Represents shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. Bay City Capital Management V LLC ("GP V") is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, "BCC V"). Bay City Capital, LLC ("BCC LLC") is the manager of GP V. The Reporting Person is an advisor of BCC LLC and a member of GP V and and shares voting and dispositive power with respect to shares held by BCC V. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. Bay City Capital Management V LLC ("GP V") is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, "BCC V"). Bay City Capital, LLC ("BCC LLC") is the manager of GP V. The Reporting Person is an advisor of BCC LLC and a member of GP V and and shares voting and dispositive power with respect to shares held by BCC V. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein

F2: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant.

ReShape Weightloss Inc.

Report date May 25, 2017 · Filed May 31, 2017 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote.0 Reported balance After 2017-05-25 transaction · row 1 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 1 · 2017-05-25 · Sale · Disposed 4,571 · Balance 0

F2: This amendment is filed to correct the transaction code to note that shares sold were disposed of rather than acquired.

F1: The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range.

F3: Represents shares held by Bay City Capital Fund IV, L.P. ("Fund IV"), including the shares held by Dr. Goldfischer; and indirect interests of Bay City Capital LLC ("BCC"), the manager of Bay City Capital Management IV LLC ("Management IV"), and Management IV, the general partner of Fund IV. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnote.0 Reported balance After 2017-05-25 transaction · row 2 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 2 · 2017-05-25 · Sale · Disposed 97 · Balance 0

F2: This amendment is filed to correct the transaction code to note that shares sold were disposed of rather than acquired.

F1: The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range.

F4: Represents shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. ("Co-Investment IV"), including the shares held by Dr. Goldfischer; and indirect interests of BCC, the manager of Management IV, and Management IV, the general partner of Co-Investment IV. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range.

F2: This amendment is filed to correct the transaction code to note that shares sold were disposed of rather than acquired.

F3: Represents shares held by Bay City Capital Fund IV, L.P. ("Fund IV"), including the shares held by Dr. Goldfischer; and indirect interests of Bay City Capital LLC ("BCC"), the manager of Bay City Capital Management IV LLC ("Management IV"), and Management IV, the general partner of Fund IV. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.

F4: Represents shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. ("Co-Investment IV"), including the shares held by Dr. Goldfischer; and indirect interests of BCC, the manager of Management IV, and Management IV, the general partner of Co-Investment IV. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Epizyme, Inc.

Report date August 12, 2022 · Filed August 16, 2022

Section 16 reporting ended · disclosed 2022-08-16. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, par value $0.0001SEC Table I · non-derivativeDirect0 Ending reported balance After 2022-08-12 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2022-08-12 · Disposition to issuer · Disposed 13,060 · Balance 8,994

F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.

Row 2 · 2022-08-12 · Disposition to issuer · Disposed 8,994 · Balance 0

F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.

Common Stock, par value $0.0001SEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2022-08-12 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2022-08-12 · Disposition to issuer · Disposed 3,380,951 · Balance 0

F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.

F3: Represents shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. Bay City Capital Management V LLC ("GP V") is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, "BCC V"). Bay City Capital, LLC ("BCC LLC") is the manager of GP V. The Reporting Person is an investment partner and managing director of BCC LLC and shares voting and dispositive power with respect to shares held by BCC V. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.

F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.

F3: Represents shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. Bay City Capital Management V LLC ("GP V") is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, "BCC V"). Bay City Capital, LLC ("BCC LLC") is the manager of GP V. The Reporting Person is an investment partner and managing director of BCC LLC and shares voting and dispositive power with respect to shares held by BCC V. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 18, 2025 Filed Jun 20, 2025 07:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 GrantStock Option (right to buy) · Derivative 1,440 $0.00 Strike: $3.22 $0.00
Disclosure

SEC source: 0000950170-25-088162 · ownership.xml · derivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,440

Underlying: Common Stock · 1,440 shares

Expires 2035-06-18

F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

Read SEC document
June 20, 2024 Filed Jun 21, 2024 16:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 GrantStock Option (right to buy) · Derivative 36,000 $0.00 Strike: $0.49 $0.00
Disclosure

SEC source: 0000950170-24-076187 · ownership.xml · derivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2034-06-19

F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 20, 2024, the date of the Issuer's 2024 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

Read SEC document
June 14, 2023 Filed Jun 15, 2023 16:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 GrantStock Option (right to buy) · Derivative 36,000 $0.00 Strike: $2.12 $0.00
Disclosure

SEC source: 0001209191-23-037285 · doc4.xml · derivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2033-06-13

F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2023, the date of the Issuer's 2023 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

Read SEC document
August 12, 2022 Filed Aug 16, 2022 19:02 UTC Epizyme, Inc. EPZM · Entity 12703 Disposition to issuerCommon Stock, par value $0.0001 3,380,951 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-028874 · doc4.xml · nonDerivative · entry 3

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · shares: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.

F1 · price: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.

F3 · ownership.nature: Represents shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. Bay City Capital Management V LLC ("GP V") is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, "BCC V"). Bay City Capital, LLC ("BCC LLC") is the manager of GP V. The Reporting Person is an investment partner and managing director of BCC LLC and shares voting and dispositive power with respect to shares held by BCC V. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein.

Read SEC document
August 12, 2022 Filed Aug 16, 2022 19:02 UTC Epizyme, Inc. EPZM · Entity 12703 Disposition to issuerCommon Stock, par value $0.0001 8,994 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-028874 · doc4.xml · nonDerivative · entry 2

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · shares: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.

F2 · price: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.

Read SEC document
August 12, 2022 Filed Aug 16, 2022 19:02 UTC Epizyme, Inc. EPZM · Entity 12703 Disposition to issuerCommon Stock, par value $0.0001 13,060 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-028874 · doc4.xml · nonDerivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,994

F1 · shares: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.

F1 · price: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.

Read SEC document
June 14, 2022 Filed Jun 15, 2022 16:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 GrantStock Option (right to buy) · Derivative 36,000 $0.00 Strike: $1.98 $0.00
Disclosure

SEC source: 0001209191-22-036932 · doc4.xml · derivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2032-06-13

F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2022, the date of the Issuer's 2022 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

Read SEC document
June 02, 2022 Filed Jun 3, 2022 20:21 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 GrantStock Options (Right to Buy) · Derivative 8,500 $0.00 Strike: $1.07 $0.00
Disclosure

SEC source: 0001209191-22-034390 · doc4.xml · derivative · entry 2

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires 2032-06-01

F2 · derivative.exercise_date: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant.

Read SEC document
May 17, 2022 Filed May 19, 2022 16:23 UTC Epizyme, Inc. EPZM · Entity 12703 GrantStock Option (Right to Buy) · Derivative 41,006 $0.00 Strike: $0.56 $0.00
Disclosure

SEC source: 0000899243-22-018818 · doc4.xml · derivative · entry 3

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,006

Underlying: Common Stock · 41,006 shares

Expires 2032-05-16

F3 · derivative.exercise_date: This option was granted on May 17, 2022 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full.

Read SEC document
May 17, 2022 Filed May 19, 2022 16:23 UTC Epizyme, Inc. EPZM · Entity 12703 GrantCommon Stock, par value $0.0001 8,994 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-018818 · doc4.xml · nonDerivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,054

F1 · shares: Consists of shares of Common Stock issuable under 8,994 restricted stock units ("RSUs") granted on May 17, 2022, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. Each RSU represents the right to receive one share of Common Stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full.

Read SEC document
November 17, 2021 Filed Nov 19, 2021 17:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 GrantStock Option (right to buy) · Derivative 18,000 $0.00 Strike: $3.23 $0.00
Disclosure

SEC source: 0001209191-21-065841 · doc4.xml · derivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2031-11-16

F1 · security: This stock option was granted to the Reporting Person for serving as the Chair of the Board.

F2 · derivative.exercise_date: Shares subject to the option vest in equal monthly installments beginning July 1, 2021, when the Reporting Person became the Chair of the Board of the Issuer, until July 1, 2022.

Read SEC document
June 29, 2021 Filed Jun 30, 2021 18:48 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 GrantStock Options (Right to Buy) · Derivative 7,728 $0.00 Strike: $8.12 $0.00
Disclosure

SEC source: 0001209191-21-044089 · doc4.xml · derivative · entry 2

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,728

Underlying: Common Stock · 7,728 shares

Expires 2031-06-28

F2 · derivative.exercise_date: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant.

Read SEC document
June 11, 2021 Filed Jun 15, 2021 16:35 UTC Epizyme, Inc. EPZM · Entity 12703 GrantStock Option (Right to Buy) · Derivative 40,559 $0.00 Strike: $8.53 $0.00
Disclosure

SEC source: 0000899243-21-023866 · doc4.xml · derivative · entry 3

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,559

Underlying: Common Stock · 40,559 shares

Expires 2031-06-10

F3 · derivative.exercise_date: This option was granted on June 11, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full.

Read SEC document
June 11, 2021 Filed Jun 15, 2021 16:35 UTC Epizyme, Inc. EPZM · Entity 12703 GrantCommon Stock, par value $0.0001 8,060 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-023866 · doc4.xml · nonDerivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,060

F1 · shares: Consists of shares of Common Stock issuable under 8,060 restricted stock units ("RSUs") granted on June 11, 2021, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. Each RSU represents the right to receive one share of Common Stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full.

Read SEC document
May 26, 2021 Filed May 28, 2021 16:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 GrantStock Option (right to buy) · Derivative 18,000 $0.00 Strike: $4.93 $0.00
Disclosure

SEC source: 0001209191-21-036507 · doc4.xml · derivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2031-05-25

F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on May 26, 2021, the date of the Issuer's 2021 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

Read SEC document
November 11, 2020 Filed Nov 13, 2020 07:05 UTC Epizyme, Inc. EPZM · Entity 12703 PurchaseCommon Stock, par value $0.0001 5,000 $12.07 $60,350.00
Disclosure

SEC source: 0000899243-20-030917 · doc4.xml · nonDerivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.98 per share to $12.10 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Read SEC document
November 02, 2020 Filed Nov 4, 2020 20:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 ConversionSeries D Preferred Stock · Derivative 3,688 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-030416 · doc4.xml · derivative · entry 7

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,587 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

F4 · derivative.exercise_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

F4 · derivative.expiration_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

Read SEC document
November 02, 2020 Filed Nov 4, 2020 20:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 ConversionSeries C-3 Preferred Stock · Derivative 7,475 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-030416 · doc4.xml · derivative · entry 6

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 19,432 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

F4 · derivative.exercise_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

F4 · derivative.expiration_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: These shares are held by Bay City Capital Fund V Co-Investment Fund, L.P. ("Co-Investment V").

F3 · ownership.nature: The Reporting Person is an Investment Partner and Managing Director of Bay City Capital LLC, the manager of Bay City Capital Management V LLC ("Management V"). Management V is the general partner of Fund V and Co-Investment V. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to the shares held by Fund V and Co-Investment V. Dr. Goldfischer disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.

Read SEC document
November 02, 2020 Filed Nov 4, 2020 20:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 ConversionSeries C-3 Preferred Stock · Derivative 392,367 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-030416 · doc4.xml · derivative · entry 5

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,020,036 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

F4 · derivative.exercise_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

F4 · derivative.expiration_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

F1 · ownership.nature: These shares are held by Bay City Capital Fund V, L.P. ("Fund V").

F3 · ownership.nature: The Reporting Person is an Investment Partner and Managing Director of Bay City Capital LLC, the manager of Bay City Capital Management V LLC ("Management V"). Management V is the general partner of Fund V and Co-Investment V. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to the shares held by Fund V and Co-Investment V. Dr. Goldfischer disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.

Read SEC document
November 02, 2020 Filed Nov 4, 2020 20:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 ConversionCommon Stock 19,432 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-030416 · doc4.xml · nonDerivative · entry 3

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 19,432

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: These shares are held by Bay City Capital Fund V Co-Investment Fund, L.P. ("Co-Investment V").

F3 · ownership.nature: The Reporting Person is an Investment Partner and Managing Director of Bay City Capital LLC, the manager of Bay City Capital Management V LLC ("Management V"). Management V is the general partner of Fund V and Co-Investment V. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to the shares held by Fund V and Co-Investment V. Dr. Goldfischer disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.

Read SEC document
November 02, 2020 Filed Nov 4, 2020 20:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 ConversionCommon Stock 1,020,036 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-030416 · doc4.xml · nonDerivative · entry 2

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,020,036

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

F1 · ownership.nature: These shares are held by Bay City Capital Fund V, L.P. ("Fund V").

F3 · ownership.nature: The Reporting Person is an Investment Partner and Managing Director of Bay City Capital LLC, the manager of Bay City Capital Management V LLC ("Management V"). Management V is the general partner of Fund V and Co-Investment V. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to the shares held by Fund V and Co-Investment V. Dr. Goldfischer disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.

Read SEC document
November 02, 2020 Filed Nov 4, 2020 20:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 ConversionCommon Stock 9,587 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-030416 · doc4.xml · nonDerivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,587

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

Read SEC document
September 25, 2020 Filed Nov 4, 2020 20:00 UTC Damora Therapeutics, Inc. GLTO · Entity 4602 GrantSeries D Preferred Stock · Derivative 3,688 $27.11 $99,981.68
Disclosure

SEC source: 0000899243-20-030416 · doc4.xml · derivative · entry 4

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,688

Underlying: Common Stock · 9,587 shares

Expires not disclosed

F4 · derivative.exercise_price: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

F5 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F4 · derivative.exercise_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

F4 · derivative.expiration_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

Read SEC document
May 29, 2020 Filed Jun 2, 2020 16:16 UTC Epizyme, Inc. EPZM · Entity 12703 GrantStock Option (Right to Buy) · Derivative 14,013 $0.00 Strike: $17.55 $0.00
Disclosure

SEC source: 0000899243-20-014898 · doc4.xml · derivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,013

Underlying: Common Stock · 14,013 shares

Expires 2030-05-28

F1 · derivative.exercise_date: This option will vest in full on May 29, 2021, subject to Reporting Person's continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full.

Read SEC document
March 16, 2020 Filed Mar 16, 2020 17:12 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 GrantStock Option (right to buy) · Derivative 15,457 $0.00 Strike: $16.00 $0.00
Disclosure

SEC source: 0000899243-20-008488 · doc4.xml · derivative · entry 9

GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner

BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner

Bay City Capital Management V LLC · CIK 0001461543 · 10% owner

Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner

Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Bay City Capital LLC

Disclosed balance after: 15,457

Underlying: Common Stock · 15,457 shares

Expires 2030-03-15

F7 · derivative.exercise_date: The option vests in three equal installments on March 16, 2021, 2022 and 2023.

F8 · ownership.nature: The securities are held directly by Bay City Capital LLC ("BCC LLC") and represent stock options granted to Dr. Goldfischer and transferred to BCC LLC pursuant to an agreement between Dr. Goldfischer and BCC LLC. Dr. Goldfischer disclaims beneficial ownership over the securities owned by BCC LLC except to the extent of his pecuniary interest, if any, in the securities by virtue of his role as managing director of BCC LLC. This report shall not be deemed an admission that the Dr. Goldfischer is the beneficial owner of such shares.

Read SEC document
March 16, 2020 Filed Mar 16, 2020 17:12 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 ConversionSeries B Preferred Stock · Derivative 16,103 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-008488 · doc4.xml · derivative · entry 8

GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner

BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner

Bay City Capital Management V LLC · CIK 0001461543 · 10% owner

Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner

Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By entities affiliated with Bay City Capital LLC

Disclosed balance after: 0

Underlying: Common Stock · 2,555 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F6 · price: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F6 · derivative.exercise_date: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F6 · derivative.expiration_date: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors.

F3 · ownership.nature: Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.

Read SEC document
March 16, 2020 Filed Mar 16, 2020 17:12 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 ConversionSeries B Preferred Stock · Derivative 845,008 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-008488 · doc4.xml · derivative · entry 7

GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner

BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner

Bay City Capital Management V LLC · CIK 0001461543 · 10% owner

Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner

Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By entities affiliated with Bay City Capital LLC

Disclosed balance after: 0

Underlying: Common Stock · 134,148 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F6 · price: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F6 · derivative.exercise_date: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F6 · derivative.expiration_date: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors.

F2 · ownership.nature: Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.

Read SEC document
March 16, 2020 Filed Mar 16, 2020 17:12 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 ConversionSeries A Preferred Stock · Derivative 61,378 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-008488 · doc4.xml · derivative · entry 6

GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner

BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner

Bay City Capital Management V LLC · CIK 0001461543 · 10% owner

Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner

Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By entities affiliated with Bay City Capital LLC

Disclosed balance after: 0

Underlying: Common Stock · 9,741 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F5 · price: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F5 · derivative.exercise_date: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F5 · derivative.expiration_date: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors.

F3 · ownership.nature: Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.

Read SEC document
March 16, 2020 Filed Mar 16, 2020 17:12 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 ConversionSeries A Preferred Stock · Derivative 3,220,915 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-008488 · doc4.xml · derivative · entry 5

GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner

BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner

Bay City Capital Management V LLC · CIK 0001461543 · 10% owner

Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner

Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By entities affiliated with Bay City Capital LLC

Disclosed balance after: 0

Underlying: Common Stock · 511,335 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F5 · price: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F5 · derivative.exercise_date: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F5 · derivative.expiration_date: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors.

F2 · ownership.nature: Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.

Read SEC document
March 16, 2020 Filed Mar 16, 2020 17:12 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 ConversionSeries Seed Preferred Stock · Derivative 5,372 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-008488 · doc4.xml · derivative · entry 4

GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner

BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner

Bay City Capital Management V LLC · CIK 0001461543 · 10% owner

Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner

Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By entities affiliated with Bay City Capital LLC

Disclosed balance after: 0

Underlying: Common Stock · 852 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F4 · price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F4 · derivative.exercise_date: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F4 · derivative.expiration_date: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors.

F3 · ownership.nature: Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.

Read SEC document
March 16, 2020 Filed Mar 16, 2020 17:12 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 ConversionSeries Seed Preferred Stock · Derivative 281,878 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-008488 · doc4.xml · derivative · entry 3

GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner

BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner

Bay City Capital Management V LLC · CIK 0001461543 · 10% owner

Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner

Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By entities affiliated with Bay City Capital LLC

Disclosed balance after: 0

Underlying: Common Stock · 44,749 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F4 · price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F4 · derivative.exercise_date: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F4 · derivative.expiration_date: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors.

F2 · ownership.nature: Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.

Read SEC document
March 16, 2020 Filed Mar 16, 2020 17:12 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 ConversionCommon Stock 13,148 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-008488 · doc4.xml · nonDerivative · entry 2

GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner

BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner

Bay City Capital Management V LLC · CIK 0001461543 · 10% owner

Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner

Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By entities affiliated with Bay City Capital LLC

Disclosed balance after: 703,380

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors.

F3 · ownership.nature: Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.

Read SEC document
March 16, 2020 Filed Mar 16, 2020 17:12 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 ConversionCommon Stock 690,232 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-008488 · doc4.xml · nonDerivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner

BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner

Bay City Capital Management V LLC · CIK 0001461543 · 10% owner

Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner

Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By entities affiliated with Bay City Capital LLC

Disclosed balance after: 690,232

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors.

F2 · ownership.nature: Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.

Read SEC document
May 31, 2019 Filed Jun 7, 2019 16:28 UTC Epizyme, Inc. EPZM · Entity 12703 GrantStock Option (Right to Buy) · Derivative 17,633 $0.00 Strike: $13.74 $0.00
Disclosure

SEC source: 0000899243-19-016018 · doc4.xml · derivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,633

Underlying: Common Stock · 17,633 shares

Expires 2029-05-30

F1 · derivative.exercise_date: This option will vest in full on May 31, 2020, subject to Reporting Person's continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full.

Read SEC document
February 07, 2019 Filed Feb 8, 2019 20:21 UTC CymaBay Therapeutics, Inc. CBAY · Entity 92768 Exercise / conversionStock Option (right to buy) · Derivative 9,340 $0.00 Strike: $5.50 $0.00
Disclosure

SEC source: 0001333277-19-000034 · edgar.xml · derivative · entry 5

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,340 shares

Expires 2027-06-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
February 07, 2019 Filed Feb 8, 2019 20:21 UTC CymaBay Therapeutics, Inc. CBAY · Entity 92768 Exercise / conversionStock Option (right to buy) · Derivative 2,335 $0.00 Strike: $5.00 $0.00
Disclosure

SEC source: 0001333277-19-000034 · edgar.xml · derivative · entry 4

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,335 shares

Expires 2023-12-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
February 07, 2019 Filed Feb 8, 2019 20:21 UTC CymaBay Therapeutics, Inc. CBAY · Entity 92768 SaleCommon Stock 11,675 $9.02 $105,328.35
Disclosure

SEC source: 0001333277-19-000034 · edgar.xml · nonDerivative · entry 3

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 07, 2019 Filed Feb 8, 2019 20:21 UTC CymaBay Therapeutics, Inc. CBAY · Entity 92768 Exercise / conversionCommon Stock 9,340 $5.50 $51,370.00
Disclosure

SEC source: 0001333277-19-000034 · edgar.xml · nonDerivative · entry 2

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,675

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 07, 2019 Filed Feb 8, 2019 20:21 UTC CymaBay Therapeutics, Inc. CBAY · Entity 92768 Exercise / conversionCommon Stock 2,335 $5.00 $11,675.00
Disclosure

SEC source: 0001333277-19-000034 · edgar.xml · nonDerivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,335

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 29, 2019 Filed Jan 31, 2019 17:20 UTC CymaBay Therapeutics, Inc. CBAY · Entity 92768 GrantStock Option (right to buy) · Derivative 27,705 $0.00 Strike: $8.43 $0.00
Disclosure

SEC source: 0001333277-19-000020 · edgar.xml · derivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,705

Underlying: Common Stock · 27,705 shares

Expires 2029-01-28

F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2019.

Read SEC document
May 18, 2018 Filed May 31, 2018 16:24 UTC Epizyme, Inc. EPZM · Entity 12703 GrantStock Option (Right to Buy) · Derivative 12,500 $0.00 Strike: $17.00 $0.00
Disclosure

SEC source: 0001209191-18-034362 · doc4.xml · derivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2028-05-17

F1 · derivative.exercise_date: This option was granted on May 18, 2018, pursuant to the Company's 2013 Stock Incentive Plan with respect to 12,500 shares of Common Stock and vests in full on May 18, 2019 and, in the event of a change in control of the Company, the vesting will accelerate in full.

Read SEC document
March 22, 2018 Filed Mar 23, 2018 16:56 UTC CymaBay Therapeutics, Inc. CBAY · Entity 92768 Exercise / conversionStock Option (right to buy) · Derivative 5,660 $0.00 Strike: $5.50 $0.00
Disclosure

SEC source: 0001333277-18-000035 · edgar.xml · derivative · entry 6

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,340

Underlying: Common Stock · 5,660 shares

Expires 2027-06-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from June 1, 2017.

Read SEC document
March 22, 2018 Filed Mar 23, 2018 16:56 UTC CymaBay Therapeutics, Inc. CBAY · Entity 92768 Exercise / conversionStock Option (right to buy) · Derivative 2,870 $0.00 Strike: $5.00 $0.00
Disclosure

SEC source: 0001333277-18-000035 · edgar.xml · derivative · entry 5

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,870 shares

Expires 2024-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
March 22, 2018 Filed Mar 23, 2018 16:56 UTC CymaBay Therapeutics, Inc. CBAY · Entity 92768 Exercise / conversionStock Option (right to buy) · Derivative 6,470 $0.00 Strike: $5.00 $0.00
Disclosure

SEC source: 0001333277-18-000035 · edgar.xml · derivative · entry 4

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,470 shares

Expires 2023-10-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
March 22, 2018 Filed Mar 23, 2018 16:56 UTC CymaBay Therapeutics, Inc. CBAY · Entity 92768 SaleCommon Stock 15,000 $13.03 $195,375.00
Disclosure

SEC source: 0001333277-18-000035 · edgar.xml · nonDerivative · entry 3

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.00 to $13.15, inclusive. The reporting person undertakes tp provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 22, 2018 Filed Mar 23, 2018 16:56 UTC CymaBay Therapeutics, Inc. CBAY · Entity 92768 Exercise / conversionCommon Stock 5,660 $5.50 $31,130.00
Disclosure

SEC source: 0001333277-18-000035 · edgar.xml · nonDerivative · entry 2

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 22, 2018 Filed Mar 23, 2018 16:56 UTC CymaBay Therapeutics, Inc. CBAY · Entity 92768 Exercise / conversionCommon Stock 9,340 $5.00 $46,700.00
Disclosure

SEC source: 0001333277-18-000035 · edgar.xml · nonDerivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,340

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 24, 2018 Filed Jan 26, 2018 17:00 UTC CymaBay Therapeutics, Inc. CBAY · Entity 92768 GrantStock Option (right to buy) · Derivative 16,000 $0.00 Strike: $11.69 $0.00
Disclosure

SEC source: 0001333277-18-000020 · edgar.xml · derivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2028-01-23

F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly beginning January 1, 2018.

Read SEC document
November 02, 2017 Filed Nov 6, 2017 20:45 UTC CymaBay Therapeutics, Inc. CBAY · Entity 92768 Exercise / conversionStock Option (right to buy) · Derivative 9,000 $0.00 Strike: $2.97 $0.00
Disclosure

SEC source: 0001209191-17-059524 · doc4.xml · derivative · entry 5

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,000 shares

Expires 2025-06-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
November 02, 2017 Filed Nov 6, 2017 20:45 UTC CymaBay Therapeutics, Inc. CBAY · Entity 92768 Exercise / conversionStock Option (right to buy) · Derivative 9,000 $0.00 Strike: $1.72 $0.00
Disclosure

SEC source: 0001209191-17-059524 · doc4.xml · derivative · entry 4

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,000 shares

Expires 2026-06-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.